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 CLINICAL PRESENTATION
A 62 -year -old woman was referred to nephrology 
section for renal dysfunction. Initial laboratory workup 
was significant for a creatinine of 3.1 mg/dl, urea 119 
mg/dl, and urinalysis showing haematuria (3+ red blood 
cells) and proteinuria (protein excretion 2+; 3.5 g/day). 
A renal ultrasound showed normal -sized kidneys, with 
sinusal hyperechogenicity.
Her past medical history was significant for smoking from 
a young age, arterial hypertension, dyslipidaemia and hypo-
thyroidism. Her habitual medication was 8 mg perindopril, 
5 mg atorvastatin and 0.05 mg levothyroxine sodium. There 
was no family history of renal disease. Serum complement 
levels (C3 and C4) were within the normal range; antinu-
clear antibodies (ANA), anti -neutrophil cytoplasmic anti-
body (C -ANCA), proteinase 3 anti -neutrophil cytoplasmic 
antibody (PR3 -ANCA) and anti -glomerular basement mem-
brane (GBM) antibodies were negative. Serology for hepa-
titis B, hepatitis C and HIV was negative.
By the time of the next visit she presented with a rapid 
decline in renal function, with an increase in serum cre-
atinine and in serum urea to 4.3 mg/dl and 152 mg/dl, 
respectively.
A kidney biopsy was performed.
 HISTOLOGY
Figure 1, 2 and 3 represent the routine staining pre-
pared in formaldehyde -fixed paraffin -embedded tissue 
in all kidney biopsy specimens: Periodic acid -Schiff, 
Masson’s trichrome and methenamine silver, respec-
tively. In all of them we can observe that the glomerular 
tuft contains remarkably enlarged podocytes. The cyto-
plasm cells are finely vacuolated, lacy, with a honey-
comb appearance.
No other cells in the biopsy had cytoplasm vacuolisation. 
Two glomeruli were globally sclerosed. Interstitial fibrosis 
and tubular atrophy were extensive. An arciform artery 
presented a substantial intimal fibrotic thickening.
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In figure 4 we observe birefringence of lipid inclu-
sions under polarized light.
In Figure 5 we can observe yellow auto -fluorescence 
of lipid inclusions under UV light.
The routine immunofluorescence performed in fro-
zen tissue was negative.
Glutaraldehyde -fixed tissue was not available and 
electron microscopy was not performed.
 BIOCHEMICAL AND GENETIC STUDY
Following the kidney biopsy specimen analysis, total 
blood sample was sent to the Doutor Jacinto de Magal-
hães Medical Genetic Centre. Biochemical study reveal 
that leukocyte enzymatic activity alpha -galactosidase 
A was partially decreased: 21 nmol/h/ml protein (nor-
mal range: 36 -80). GLA gene was resequenced and the 
heterozygous mutation c.337T>C (p.F113L) was found 
in exon 2.








Frozen unstained tissue under polarized light, X400
 
Figure 5
Frozen unstained tissue under UV light, X400, auto-fluorescence 
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 ANATOMO ‑CLINICAL DIAGNOSIS
Fabry disease
 EVOLUTION AND TREATMENT
Renal function remains stable with 3.87 mg/dl of 
creatinine and 141 mg/dl of urea. Further study was 
required to evaluate the extent of the disease in other 
organs. The enzyme replacement was solicited and is 
awaiting approval.
Screening for Fabry disease was performed in the 
patient’s daughter. Leukocyte enzymatic activity alpha-
-galactosidase A was in normal range and no mutation 
was found in GLA gene.
 DISCUSSION
Fabry disease is a lysosomal storage disease caused 
by an x -linked deficiency in alpha - galactosidase A enzyme 
(αGal)­leading­to­accumulation­of­globotriaosylceramide­
(GL3) in many cell types. The disease affects the function 
of the kidney, heart, sweat glands and nerves. The clinical 
manifestations vary with mutation and consequent level 
of­αGal.­Female­patients­may­show­distinct­phenotypes­
from asymptomatic to renal failure.1,2
In the formaldehyde -fixed paraffin -embedded sec-
tions the cellular lipids deposits are removed during 
processing and the routine stains demonstrate only 
vacuolated cells (Figures 1 ‑3).
Podocytes present pale, enlarged, lacy cytoplasm 
with honeycomb appearance. Similar changes are pre-
sent to a lesser degree in endothelial and mesangial 
cells and occasionally in the parietal epithelial cells. A 
similar vacuolated appearance could be present in 
tubular epithelial cells, particularly in distal tubules. 
Small arteries and arterioles show vacuolation of the 
endothelial cells and finely vacuolated areas in the 
smooth muscle3.
Progression of the disease leads to chronic unspecific 
glomerular, vessel and tubulo -interstitial lesions: 
mesangial increased cellularity and matrix, segmental 
glomerular sclerosis, capillary wall thickening, arterial 
and arteriolar sclerosis and tubular atrophy/ interstitial 
fibrosis3.
Routine immunofluorescence (IgG, IgA, IgM, C3, C4, 
C1q, fibrinogen, albumin, kappa and lambda light chain) 
is negative. It could be positive but unspecific, with 
focal C3 and IgM deposition in sclerosed glomerular 
area4.
Fabry deposits are demonstrated using glutaralde-
hyde-fixed and epon -embedded kidney tissue3 -4. With 
that processing the lipid deposits are not removed 
and can be demonstrated by toluidine blue staining 
in 1 micron -thick sections and by electron microscopy 
(EM).
Electron microscopy shows enlarged secondary 
lysosomes filled with granular to lamellated mem-
brane structures that have an onion -skin -like appear-
ance or parallel dense layers (zebra bodies). These 
inclusions in EM are considered the hallmark of gly-
colipid storage5.
Our patient has only formaldehyde and frozen tissue, 
without glutaraldehyde -fixed tissue, and so toluidine 
blue and EM could not be usefully performed to confirm 
the diagnosis of Fabry disease.
The storage material not removed in frozen 
unstained kidney tissue3,4,6 is birefringent under 
polarized light (Figure 4) and exhibits auto -fluorescence 
(Figure 5).
Affected males with classic and variant phenotypes 
are reliably diagnosed by the demonstration of deficient 
enzyme activity in leukocytes. Genetic testing is 
required in females and in males with borderline levels 
of alpha -galactosidase A activity.
Since more than 700 distinct mutations have thus 
far been described, identification of a mutation in a 
new family requires complete resequencing of the gene 
in an experienced laboratory7.
The genetic study of our patient was performed in 
a selected laboratory and one of the first mutations 
described as causal of Fabry disease was found8.
The lesions observed in formaldehyde -fixed paraffin-
-embedded and in frozen renal tissue, the partial 
decrease in leukocytes’ alpha -galactosidase A enzy-
matic activity and the heterozygous mutation c.337T>C 
(p.F113L) allows the diagnosis of Fabry disease in our 
female patient.
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